Dermatitis News

Recent data provide evidence that the onset of upper airway edema symptoms occur as quickly as 30 minutes from onset to maximum airway involvement, suggesting patient education to avoid morbidity and mortality.

Symptoms associated with atopic dermatitis appeared to persist into the second decade of children’s lives and possibly longer, making it a probable lifelong illness, according to recent study results.

Atopic dermatitis was often associated with food sensitization among adult patients; and the percentage of sensitization to animal food allergens appeared significantly greater among those with severe atopic dermatitis, according to data.

In patients with severe cutaneous adverse reactions related to systemic antibiotics, the presence of underlying comorbidities may contribute to increased mortality, according to recent findings from Taiwan.

Evidence suggests that coagulation, fibrinolysis and accompanying systems have a role in chronic urticaria pathogenesis and that evaluating their biomarkers may aid in disease management, according to a review article published in Allergy.

Multiple factors influenced the complex nature of chronic pruritus and affected the quality of life in patients with the condition, according to results from nationwide telephone surveys.

Women who experience adverse life events during the second half of gestation are more likely to increase a child’s risk for atopic disorders, asthma and eczema, according to researchers.

DENVER — Advanced melanoma staging with updates on future therapies, the latest acne treatments, and laser and botulinum toxin A treatments for wounded warrior traumatic injuries are highlights of the American Academy of Dermatology annual meeting beginning today.

PuraCap Pharmaceutical has announced its participation in a phase 2 trial to assess daily treatment of its topical ceramide-dominant complete lipid mixture to prevent eczema in infants at risk for allergic conditions.

SAN DIEGO — Patients with moderate-to-severe atopic dermatitis treated with dupilumab monotherapy displayed rapid improvement in disease activity and pruritus compared with those treated with placebo, according to late-breaking data presented at the 2014 American Academy of Allergy, Asthma & Immunology annual meeting.